ArticleDiscover oncology2025
Changes in pulmonary function of CT-guided microwave ablation for patients with pulmonary ground-glass nodules after lobectomy: a retrospective, observation study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis retrospective study aimed to investigate changes in pulmonary function among patients undergoing computed tomography (CT)-guided microwave ablation (MWA) for the treatment of pulmonary ground-glass nodules following lobectomy. MATERIALS AND
methodsFifty-two patients with pulmonary ground-glass nodules (GGN) who underwent lobectomy and were subsequently diagnosed with non-small cell lung cancer (NSCLC) were included in the study. Pulmonary function tests (PFTs) were conducted at baseline and again 1 month after microwave ablation (MWA). The assessed parameters included vital capacity (VC), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1 percentage (FEV1%), peak expiratory flow (PEF), maximal voluntary ventilation (MVV), and maximum mid-expiratory flow (MMEF). The measurements obtained 1-month post-MWA were compared to the baseline values.
resultsThe mean values for VC, FVC, FEV1, FEV1%, MMEF, PEF, and MVV at baseline and 1-month post-MWA for all patients were as follows: VC (3.01 ± 0.68vs. 2.88 ± 0.67, P = 0.348), FVC (3.07 ± 0.75 vs. 2.95 ± 0.69, P = 0.430), FEV1 (2.29 ± 0.61 vs. 2.14 ± 0.55, P = 0.228), FEV1% (74.26 ± 7.70 vs. 72.41 ± 9.40, P = 0.316), MMEF (1.88 ± 0.81 vs. 1.74 ± 0.72, P = 0.410), PEF (5.03 ± 1.62 vs. 4.54 ± 1.53, P = 0.179), and MVV (77.69 ± 22.21 vs. 73.15 ± 17.63, P = 0.286). For the eight patients who underwent ablation of two or more lesions simultaneously, the mean values for VC, FVC, FEV1, FEV1%, MMEF, PEF, and MVV at baseline and 1 month post-MWA were as follows: VC (2.67 ± 0.90vs. 3.05 ± 0.97, P = 0.341), FVC (2.82 ± 0.94vs. 3.10 ± 0.92, P = 0.430), FEV1 (1.97 ± 0.69vs. 2.07 ± 0.69, P = 0.709), FEV1% (70.01 ± 7.24 vs. 66.27 ± 4.47, P = 0.082), MMEF (1.28 ± 0.80 vs. 1.35 ± 0.58, P = 0.777), PEF (4.43 ± 1.44 vs. 3.87 ± 1.40, P = 0.074), and MVV (65.22 ± 16.50 vs. 72.26 ± 12.28, P = 0.222). No significant differences were observed in the PFT results before and 1 month after MWA.
conclusionsMWA is a localized treatment that spares lung parenchyma. The pulmonary function 1 month after MWA did not statistically differ from baseline levels, suggesting that MWA may not adversely affect pulmonary function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.